Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-11

Study Completion Date

2024-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of a personalized vaccine (PEV) based on GAd-PEV priming and MVA-PEV boosting, combined with SoC first-line immunotherapy using an anti-PD-1 checkpoint inhibitor in patients with unresectable stage III/IV cutaneous melanoma or with stage IV NSCLC (PDL1 ≥ 50%). The PEV vaccines will be prepared on an individual basis, following a tumor biopsy performed at the time of screening and subsequent NGS analysis, to identify patient-specific tumor mutations. Both neoantigen-encoding genetic vaccines are administered intramuscularly using 1 prime with GAd-PEV and 3 boosts with MVA-PEV in combination with the licensed programmed death receptor-1 (PD-1)-blocking antibody pembrolizumab in adult patients in patients with unresectable stage III/IV cutaneous melanoma (Cohort a) or with stage IV NSCLC (PDL1 ≥ 50%) (Cohort b).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT02477826

Non-Small Cell Lung Cancer

COMPLETED PHASE3

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

NCT04956692

Non-Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE3

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

NCT03770299

Non-Small Cell Lung Cancer Non-Small-Cell Lung Carcinoma Circulating Tumor DNA

WITHDRAWN PHASE2

Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer

NCT03568097

Small Cell Lung Carcinoma

UNKNOWN PHASE2

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

NCT01840579

Solid Tumor Non-small Cell Lung Cancer Small Cell Lung Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Overall Study Design:

• This is an open-label, non-randomized, dose-confirmation and cohort expansion phase 1b first-in-human study, in which 28 patients, expandable up to 34 evaluable patients in case of DLT.

Study IMPs:

Nous-PEV vaccine is composed of 2 sets of IMPs:

* GAd-PEV
* MVA-PEV

Treatment phases:

A) Induction phase with pembrolizumab (cycles 1, 2 and 3). B) Priming phase including 1 GAd-PEV administration with pembrolizumab (cycle 4).

C) Boosting phase including 3 boosting administrations of MVA-PEV with pembrolizumab (cycles 5, 6 and 7).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma (Skin) Non-Small-Cell Lung Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Treatment Cohorts of the study.

Part 1:

• Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.

Part 2

* Cohort 2a: 13 patients with unresectable stage III / IV Cutaneous Melanoma.
* Cohort 2b:12 patients with stage IV NSCLC (PDL1≥ 50%). In all cohorts, the treatment consists of four Nous-PEV vaccine administrations in combination with pembrolizumab as SoC.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1a

Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.

Group Type EXPERIMENTAL

GAd-PEV

Intervention Type BIOLOGICAL

Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

MVA-PEV

Intervention Type BIOLOGICAL

Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).

Cohort 2a

Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.

Group Type EXPERIMENTAL

GAd-PEV

Intervention Type BIOLOGICAL

Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

MVA-PEV

Intervention Type BIOLOGICAL

Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).

Cohort 2b

Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).

Group Type EXPERIMENTAL

GAd-PEV

Intervention Type BIOLOGICAL

Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

MVA-PEV

Intervention Type BIOLOGICAL

Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GAd-PEV

Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).

Intervention Type BIOLOGICAL

MVA-PEV

Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years.
2. Patients with histologically or cytologically confirmed unresectable stage III or stage IV Cutaneous Melanoma, as per AJCC staging system (8th edition). First-line treatment-naive patients.
3. Participation in this trial will be dependent upon supplying tumor tissue from newly obtained specimen. Newly obtained biopsies of a tumor lesion, not previously irradiated, must be provided in the form of excisional biopsies, resected tissue or core needle biopsies.
4. Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1 by the local site Investigator / radiologist assessment
5. Presence of at least one lesion amenable to repeated biopsy, ideally not the one being used for measuring.
6. Willingness to undergo a minimum of two fresh lesion biopsies (pre-treatment and on-treatment).
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
8. Life expectancy of at least 12 months.
9. Adequate renal, hepatic, and hematologic functions
10. A female patient is eligible to participate if she is not pregnant and not breastfeeding
11. A male patient must agree to use an adequate contraception

1. Age ≥ 18 years.
2. Histologically or cytologically confirmed stage IV squamous or non-squamous NSCLC without EGFR or ALK/ROS1 /RET genomic alteration.
3. Tumor expression with PD-L1 ≥50% tumor proportion score (TPS).
4. First-line treatment-naïve patients.
5. Participation in this trial will be dependent upon supplying tumor tissue from a newly obtained specimen. Newly obtained biopsies of a tumor lesion, not previously irradiated, must be provided in the form of excisional biopsies, resected tissue or core needle biopsies.
6. Presence of at least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 as determined by the local site Investigator / radiologist assessment.
7. Presence of at least one tumor lesion amenable to repeated biopsy, if possible, ideally not the one being used for measuring.
8. Willingness to undergo a minimum of two fresh tumor biopsies (pre-treatment and on-treatment).
9. ECOG performance status 0 to 1.
10. Life expectancy of at least 6 months.
11. Adequate renal, hepatic, and hematologic functions
12. A female patient is eligible to participate if she is not pregnant and not breastfeeding
13. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.

Exclusion Criteria

1. Currently receiving treatment with another investigational medicinal product.
2. Prior therapy with immune checkpoint inhibitors. Patients must not have received any investigational immunotherapy either.
3. Prior radiotherapy within 2 weeks of enrolment, or within 4 weeks of enrolment in the case of radiation to central nervous system (CNS), which requires ≥ 4-week washout.
4. Prior allogenic tissue or solid organ transplant.
5. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids and/or whose pulse oximetry is less than 92% "on room air".
6. Limiting cardiac criteria: prolonged QT interval or QT prolongation risk factors, clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g. complete LBBB, third degree heart block, risk of arrythmic events, ejection fraction under lower limit of normal.
7. Major (according to the Investigator's judgment) surgery within 12 weeks before enrolment.
8. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.
9. Immunosuppression including the continued use of systemic (at prednisone dose equivalent of \> 10 mg) or topical steroids at or near the planned i.m. injection site or the use of immunosuppressive agents for any concurrent condition in the 4 weeks prior to first study treatment administration. Inhaled and eye drop-containing corticosteroids are permitted.
10. Previous vaccination (either therapeutic and/or prophylactic) against cancer.
11. History of autoimmune disease in the last 5 years, including any active autoimmune disease except vitiligo or childhood asthma.
12. Chronic or concurrent active infectious disease requiring systemic antibodies, antifungal, or antiviral treatment.
13. Known Medical History of human immunodeficiency virus (HIV) infection or known Medical History of acquired immunodeficiency syndrome (AIDS). HIV testing is not required unless mandated by the local health authority.
14. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment, or at risk for HBV reactivation
15. Known CNS metastasis and/or carcinomatous meningitis.
16. Known cerebral edema.
17. Live vaccine received within 30 days before treatment initiation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No